Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®

Inclusion Criteria: * must receive first oral dose of tacrolimus one day (lung, pancreas or Simultaneous Pancreas Kidney (SPK) recipients) or three days (heart recipients) after transplantation (skin closure) * negative pregnancy test prior to enrolment (females) * agree to practice effective birth control during the study * treated since transplantation with Antithymocyte globulin/ Mycophenolate Mofetil/steroids (ATG/MMF/steroids), gastric motility resumed and renal function adequate (\<230 µmol/l (\<2.6 ml/dl)) on Day 1 Exclusion Criteria: * receiving a multi-organ transplant (with the exception of SPK) or previously received an organ transplant (including re-transplantation) * pulmonary vascular resistance ≥4 Wood units despite medication * required an emergency ventricular assist device within one week prior to transplantation * significant renal impairment * significant liver disease * malignancies or a history of malignancy within the last 5 years * significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting, active upper gastrointestinal disorder that may affect the absorption of tacrolimus, or active peptic ulcer * requires systemic immunosuppressive medication for any other indication than transplantation * diagnosis of cystic fibrosis * pregnant or breast-feeding